The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Sivelestat     2-[[2-[[4-(2,2- dimethylpropanoyloxy)phenyl...

Synonyms: Silvelestat, SureCN123221, Ono-5046, ONO5046, QC-5742, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of EI 546


High impact information on EI 546


Chemical compound and disease context of EI 546


Biological context of EI 546


Anatomical context of EI 546


Associations of EI 546 with other chemical compounds


Gene context of EI 546


Analytical, diagnostic and therapeutic context of EI 546

  • The primary objectives of this study were to determine whether sivelestat would reduce 28-day all-cause mortality or increase the number of ventilator-free days (days alive and free from mechanical ventilation from day 1 to day 28) compared with placebo in mechanically ventilated patients with acute lung injury [6].
  • In a trial of ALI patients with systemic inflammatory response syndrome, conducted in Japan by Ono Pharmaceutical scientists, sivelestat treatment improved the investigator assessment of global improvement and the percentages of patients who were removed from ventilators and transferred out of the intensive care unit [2].
  • In addition, a synthetic NE inhibitor, sivelestat (ONO-5046 and LY544349), is effective in reducing measures of inflammation and injury in multiple animal models of ALI [2].
  • Levels of interleukin-6 were lower in the sivelestat group than in the controls at 24, 48, and 72 h after treatment [16].
  • Furthermore, sivelestat at 1 mg/kg/h almost totally prevented the increase in protein concentration in the bronchoalveolar lavage fluid without affecting lung neutrophil accumulation [8].


  1. Delayed neutrophil elastase inhibition prevents subsequent progression of acute lung injury induced by endotoxin inhalation in hamsters. Kawabata, K., Hagio, T., Matsumoto, S., Nakao, S., Orita, S., Aze, Y., Ohno, H. Am. J. Respir. Crit. Care Med. (2000) [Pubmed]
  2. Neutrophil elastase and acute lung injury: prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics. Zeiher, B.G., Matsuoka, S., Kawabata, K., Repine, J.E. Crit. Care Med. (2002) [Pubmed]
  3. Sivelestat, a neutrophil elastase inhibitor, attenuates neutrophil priming after hepatoenteric ischemia in rabbits. Kotake, Y., Yamamoto, M., Matsumoto, M., Morisaki, H., Takeda, J. Shock (2005) [Pubmed]
  4. Sivelestat, a specific neutrophil elastase inhibitor, prevented phorbol myristate acetate-induced acute lung injury in conscious rabbits. Hagio, T., Matsumoto, S., Nakao, S., Matsuoka, S., Kawabata, K. Pulmonary pharmacology & therapeutics. (2005) [Pubmed]
  5. Protective effects of a selective neutrophil elastase inhibitor (sivelestat) on lipopolysaccharide-induced acute dysfunction of the pulmonary microcirculation. Inoue, Y., Seiyama, A., Tanaka, H., Ukai, I., Akimau, P., Nishino, M., Shimazu, T., Sugimoto, H. Crit. Care Med. (2005) [Pubmed]
  6. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Zeiher, B.G., Artigas, A., Vincent, J.L., Dmitrienko, A., Jackson, K., Thompson, B.T., Bernard, G. Crit. Care Med. (2004) [Pubmed]
  7. Elastase inhibition reduced death associated with acid aspiration-induced lung injury in hamsters. Hagio, T., Matsumoto, S., Nakao, S., Abiru, T., Ohno, H., Kawabata, K. Eur. J. Pharmacol. (2004) [Pubmed]
  8. Inhibition of neutrophil elastase activity attenuates complement-mediated lung injury in the hamster. Hagio, T., Nakao, S., Matsuoka, H., Matsumoto, S., Kawabata, K., Ohno, H. Eur. J. Pharmacol. (2001) [Pubmed]
  9. Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines. Wada, Y., Yoshida, K., Tsutani, Y., Shigematsu, H., Oeda, M., Sanada, Y., Suzuki, T., Mizuiri, H., Hamai, Y., Tanabe, K., Ukon, K., Hihara, J. Oncol. Rep. (2007) [Pubmed]
  10. Sivelestat, a specific neutrophil elastase inhibitor, suppresses the growth of gastric carcinoma cells by preventing the release of transforming growth factor-alpha. Wada, Y., Yoshida, K., Hihara, J., Konishi, K., Tanabe, K., Ukon, K., Taomoto, J., Suzuki, T., Mizuiri, H. Cancer Sci. (2006) [Pubmed]
  11. Effects of sivelestat, a new elastase inhibitor, on IL-8 and MCP-1 production from stimulated human alveolar epithelial type II cells. Misumi, T., Tanaka, T., Mikawa, K., Nishina, K., Morikawa, O., Obara, H. Journal of anesthesia. (2006) [Pubmed]
  12. Virus Associated Hemophagocytic Syndrome Accompanied by Acute Respiratory Failure Caused by Influenza A (H3N2). Ando, M., Miyazaki, E., Hiroshige, S., Ashihara, Y., Okubo, T., Ueo, M., Fukami, T., Sugisaki, K., Tsuda, T., Ohishi, K., Yoshitake, S., Noguchi, T., Kumamoto, T. Intern. Med. (2006) [Pubmed]
  13. Epithelium-dependent and -independent inhibitory effects of sivelestat, a neutrophil elastase inhibitor, on substance P-induced contraction of airway smooth muscle in lipopolysaccharide-treated guinea-pigs. Takayama, N., Uchida, K. Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi. (2005) [Pubmed]
  14. A neutrophil elastase inhibitor, sivelestat, ameliorates lung injury after hemorrhagic shock in rats. Toda, Y., Takahashi, T., Maeshima, K., Shimizu, H., Inoue, K., Morimatsu, H., Omori, E., Takeuchi, M., Akagi, R., Morita, K. Int. J. Mol. Med. (2007) [Pubmed]
  15. Sivelestat reduces inflammatory mediators and preserves neutrophil deformability during simulated extracorporeal circulation. Matsuzaki, K., Hiramatsu, Y., Homma, S., Sato, S., Shigeta, O., Sakakibara, Y. Ann. Thorac. Surg. (2005) [Pubmed]
  16. Pilot study of the effects of ONO-5046 in patients with acute respiratory distress syndrome. Kadoi, Y., Hinohara, H., Kunimoto, F., Saito, S., Goto, F., Kosaka, T., Ieta, K. Anesth. Analg. (2004) [Pubmed]
WikiGenes - Universities